CClinicalTrials.gg
RecruitingNCT07472244ANTI-RBEUpdated Mar 16, 2026

Does the Development of the Repeated Bout Effect Depend on Oxidative Stress and Inflammation?

An interventional study of Control and Intervention in Exercise Recovery, sponsored by University of Bath. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by University of Bath · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Eccentric exercise, particularly when novel and strenuous, can cause soreness and inflammation, impairing subsequent exercise performance. These performance decrements are attributable to oxidative stress and inflammation. Interestingly, a single bout of eccentric exercise can confer protective effects, ameliorating the negative consequences in subsequent bouts. This is termed the repeated bout effect (RBE), which would be of interest to athletes considering the detrimental effects of strenuous eccentric exercise. Athletes regularly consume supplements in hope of attenuating the performance decrements after strenuous eccentric exercise

. However, considering the dose-response relationship between the initial performance decrement and the magnitude of the RBE , supplements may diminish the obtainment of the RBE. This notion remains untested, and so the proposed project is a double-blind, placebo-controlled, parallel group study aiming to assess the effects of acute vitamin C and ibuprofen supplementation on the development of the RBE. These two supplements were chosen as they are most frequently and successfully used in the literature to target oxidative stress (vitamin C) and inflammation (ibuprofen). Additionally, these doses (and the timing of supplements) were chosen to mimic protocols reporting beneficial effects

02

Conditions studied

  • Exercise Recovery
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 - 45 years of age
  • BMI 18.5 - 29.9 kg/m2
  • Able to perform 20-minutes of bench stepping exercise
  • Capable and willing to provide consent (oral and written)

Exclusion criteria

Exclusion Criteria:

  • Familiarised with bench stepping exercise procedures
  • Not cleared for exercise by health questionnaires or physical activity readiness questionnaire
  • Participants exhibiting any alteration in clinical inflammation parameters due to other cause
  • Participants currently being prescribed any anti-inflammatory medications
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Intervention

    Vitamin C and Non-steroidal anti-inflammatory drug

    Dietary Supplement: Intervention

  • Placebo comparator
    Control

    Identical Placebo

    Dietary Supplement: Control

Interventions

  • Dietary supplementControl

    Identical maltodextrin tablet. Appearance and weight matched

  • Dietary supplementIntervention

    1,000 mg Vitamin C and 400 mg non-steroidal anti-inflammatory drug every 8-h for 48-h

05

What researchers measure

Primary outcomes

  1. Muscle Function

    Jump height calculated through flight time

    Time frame: Baseline and post exercise (2 hours, 1 day, 7 day)

Secondary outcomes

  1. Muscle Function

    Peak power quantified using a Keiser Leg Press

    Time frame: Baseline and post exercise (2 hours, 1 day, 7 day)

  2. Muscle Function

    Peak force quantified using a Keiser Leg Press

    Time frame: Baseline and post exercise (2 hours, 1 day, 7 day)

  3. Muscle Function

    Peak velocity quantified using a Keiser Leg Press

    Time frame: Baseline and post exercise (2 hours, 1 day, 7 day)

  4. Creatine Kinase

    Plasma Creatine Kinase

    Time frame: Baseline and immediately, 1-h (hour)-, 2-h-, 24-h-,and 48-hours-post-exercise

06

Study locations

1 of 1 sites recruiting
  • University of Bath
    Bath, United Kingdom
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07472244
Lead sponsor
University of Bath
Responsible party
Max Davis (Chief Investigator, University of Bath) — Principal investigator
First posted
Mar 16, 2026
Start date
Sep 1, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Mar 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion